OraSure Technologies, Inc. (NASDAQ:OSUR) Files An 8-K Regulation FD Disclosure

0

OraSure Technologies, Inc. (NASDAQ:OSUR) Files An 8-K Regulation FD Disclosure

Item7.01 Regulation FD Disclosure.

On February6, 2017, DNA Genotek, Inc. (DNA Genotek), a subsidiary
of OraSure Technologies, Inc. (the Company), issued a press
release announcing the settlement of patent infringement and
breach of contract litigation filed against Ancestry.comDNA, LLC
(Ancestry) and Spectrum Solutions LLC (Spectrum). A copy of this
press release is attached as Exhibit 99.1 to this Form 8-K and is
incorporated herein by reference.

The information in this Item and attached Exhibit shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that
section, nor shall such information and Exhibit be deemed
incorporated by reference in any filing under the Securities Act
of 1933, except as shall be expressly set forth by specific
reference in such a filing. The fact that the information and
Exhibit are being furnished should not be deemed an admission as
to the materiality of any information contained therein. The
Company undertakes no duty or obligation to publicly update or
revise the information contained in this Current Report or
attached Exhibit.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits

ExhibitNumber

Description

99.1 Press Release, dated February6, 2017, Announcing Settlement
of Litigation between DNA Genotek, Inc., a subsidiary of
OraSure Technologies, Inc., and Ancestry.comDNA, LLC and
Spectrum Solutions LLC.


About OraSure Technologies, Inc. (NASDAQ:OSUR)

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests, such as OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, OraQuick HIV Self-Test, OraQuick HCV Rapid Antibody Test, OraQuick Ebola Rapid Antigen Test, OraSure QuickFlu Rapid Flu A&B Test, OraSure Collection Device, Molecular Collection Systems, Cryosurgical Systems (Skin Lesion Removal Products), Immunoassay Tests and Reagents, Western blot HIV-1 Confirmatory Test and Q.E.D. Saliva Alcohol Test. Its products are sold in the United States and internationally to clinical laboratories and hospitals.

OraSure Technologies, Inc. (NASDAQ:OSUR) Recent Trading Information

OraSure Technologies, Inc. (NASDAQ:OSUR) closed its last trading session up +0.16 at 8.94 with 266,637 shares trading hands.